Ketamine-Assisted Therapy and Spravato: Two Breakthrough Mental Health Options

Mental health treatment has evolved considerably over the past decade. For patients who have spent years trying medications, adjusting dosages, and working through therapy without finding adequate relief, two newer options have emerged that are changing what's possible: ketamine-assisted therapy and Spravato (esketamine) nasal spray. While they share some common ground, they are distinct treatments with different mechanisms, applications, and practical considerations.

This article explains how each treatment works, who they're best suited for, and how to think about them as part of a broader mental health care plan.

Understanding Ketamine-Assisted Therapy

Ketamine-assisted therapy (KAT) combines the pharmacological effects of ketamine with structured psychotherapy sessions. The idea is that ketamine's unique neurological effects can create a window of heightened neuroplasticity, during which a patient may be more open to processing difficult emotions, examining entrenched thought patterns, and engaging more deeply with therapeutic work.

In a typical KAT protocol, a patient receives a ketamine infusion or lozenge in a comfortable clinical setting, with a therapist present or available for integration sessions before and after. The therapist helps the patient prepare for the experience, guides them through it where appropriate, and supports them in making sense of any insights or emotional material that arose during the session.

The combination approach is particularly valued for conditions where trauma, deeply held negative beliefs, or treatment-resistant emotional patterns are central to the patient's struggles. Research has suggested that the neuroplasticity window opened by ketamine may help patients access and work through material that's been difficult to engage with through talk therapy alone.

Who Benefits Most from Ketamine-Assisted Therapy?

KAT is not a universal solution, but it tends to show particular promise for patients with:

Treatment-resistant depression, especially where emotional avoidance or trauma is a factor

PTSD, particularly complex or chronic presentations

Anxiety disorders with deeply ingrained cognitive patterns

End-of-life distress and existential anxiety

Substance use disorders, where some programs are incorporating ketamine alongside behavioral therapy

The structured therapeutic component is what distinguishes KAT from ketamine infusions used purely for their pharmacological effects. Both have their place, and the right choice depends on your diagnosis, your history with therapy, and your treatment goals.

What Is Spravato and How Is It Different?

Spravato is the brand name for esketamine, a nasal spray form of a ketamine-derived compound. It's the only FDA-approved ketamine-based medication for psychiatric use, and its approval was a landmark moment in the treatment of mental health conditions. The FDA approved Spravato in 2019 for treatment-resistant depression, and later for major depressive disorder with acute suicidal ideation or behavior.

Unlike IV ketamine infusions, which are not FDA-approved for psychiatric use and are administered off-label, Spravato has a formal regulatory pathway and defined treatment protocols. It must be administered in a certified healthcare setting under direct supervision, and patients must remain at the clinic for at least two hours after each dose for monitoring.

Spravato is typically used alongside an oral antidepressant rather than as a standalone treatment. The combination has been shown to produce faster and more significant improvements in depression symptoms than antidepressant medication alone.

Spravato Treatment: What to Expect

Spravato is administered as a nasal spray that patients self-administer under clinical supervision. A standard induction phase involves:

Twice-weekly sessions for four weeks

Weekly sessions for four weeks

Then individualized maintenance dosing based on response

During each session, patients self-administer the nasal spray and then rest in a supervised setting for at least two hours. Dissociative effects, dizziness, and nausea are possible during this window, which is why supervised administration and the mandatory observation period are required.

Most patients don't find the experience distressing, particularly once they know what to expect. The dissociative effects typically resolve within the observation period, and patients are asked not to drive or operate heavy machinery on the day of their session.

How Spravato Compares to Ketamine Infusions

Patients sometimes ask whether IV ketamine or Spravato is more effective. The honest answer is that it depends on the individual and the specific condition being treated.

IV ketamine has more research behind it and allows for more precise dosing, since the medication is delivered directly into the bloodstream. It tends to produce stronger acute effects and may be preferable for patients with severe, rapidly cycling symptoms.

Spravato has the advantage of FDA approval, which means it's covered by many insurance plans for qualifying diagnoses, something IV ketamine is not. The nasal spray delivery is also less invasive than an intravenous line, and the defined treatment protocol may feel more structured and reassuring for some patients.

A qualified psychiatrist can help you think through which option is more appropriate based on your diagnosis, medical history, insurance coverage, and personal preferences.

Insurance Coverage and Practical Considerations

One of the most significant practical differences between ketamine-assisted therapy and Spravato is insurance coverage. Because Spravato is FDA-approved, it's covered by most major insurance plans for patients who meet the clinical criteria, generally meaning two or more failed antidepressant trials. The prior authorization process can take some time, but a good clinic will manage this on your behalf.

IV ketamine infusions, including those used in KAT protocols, are generally not covered by insurance and are paid out of pocket. Costs vary by clinic and location, but a full course of six infusions typically ranges from $3,000 to $6,000. Some clinics offer financing options.

If insurance coverage is a key consideration for you, Spravato may be the more accessible path. If you're paying out of pocket and want the treatment with the longest clinical track record, IV ketamine has a strong evidence base.

Finding a Provider

Both ketamine-assisted therapy and Spravato should be administered by or under the supervision of a qualified psychiatrist with specific experience in these treatments. As with any specialty care, the experience and approach of the clinical team matter as much as the treatment itself.

For patients in New York City, Village TMS ketamine services include both ketamine-assisted therapy and Spravato administration in a psychiatry-led environment. Their team works with patients to determine which approach is best suited to their specific diagnosis and history, and they provide full support throughout the treatment process.

Final Thoughts

Ketamine-assisted therapy and Spravato represent two of the most significant advances in mental health treatment in recent years. They're not right for every patient, but for those who have exhausted conventional options, they offer a meaningful alternative with a growing body of clinical evidence behind them.

If you're considering either treatment, the most important first step is a thorough evaluation with a psychiatrist who is experienced in these approaches. They can help you understand whether you're a good candidate and which specific treatment is most likely to produce meaningful results for your situation.